down arrow

Viridian Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92790C1045
USD
32.46
2.03 (6.67%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

30.9133.34

52 Week

9.9033.34
Valuation
Technical
Day's Volume

CASH

1.3 M

Shareholding (Mar 2025)

FII

15.12%

Held by 87 FIIs

DII

38.04%

Held by 46 DIIs

Promoter

11.37%

How big is Viridian Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Viridian Therapeutics, Inc. has a market capitalization of 1,210.42 million and reported net sales of 0.30 million with a net profit of -293.24 million over the latest four quarters. Shareholder's funds are 671.64 million, and total assets amount to 742.40 million.

As of Jun 18, Viridian Therapeutics, Inc. has a market capitalization of 1,210.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.30 million, while the sum of net profit for the same period is -293.24 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 671.64 million, and total assets amount to 742.40 million.

Read More

What does Viridian Therapeutics, Inc. do?

22-Jun-2025

Viridian Therapeutics, Inc. is a micro-cap pharmaceutical and biotechnology company with no recent net sales and a net loss of $87 million as of March 2025. It has a market cap of approximately $1.21 billion and does not pay dividends.

Overview: <BR>Viridian Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -87 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,210.42 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -48.51% <BR>Price to Book: 2.00<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Viridian Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 13, 2023, Viridian Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics and underperformance compared to peers and the S&P 500.

As of 13 November 2023, the valuation grade for Viridian Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued given its financial metrics, including a price-to-book value of 1.98, an EV to EBITDA ratio of -1.73, and a return on equity (ROE) of -48.51%. These ratios highlight the company's struggles, particularly as it operates at a loss and shows negative capital employed.<BR><BR>In comparison to its peers, Viridian Therapeutics, Inc. stands out unfavorably against Innoviva, Inc. and Collegium Pharmaceutical, Inc., which have P/E ratios of 15.38 and 14.78, respectively. This stark contrast underscores the challenges Viridian faces in generating positive returns for investors. Furthermore, the company's stock has underperformed relative to the S&P 500, particularly year-to-date, where it has declined by 23.27% compared to the index's 2.44% gain. Overall, the combination of poor financial ratios and relative performance suggests that Viridian Therapeutics is overvalued in the current market environment.

Read More

Is Viridian Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Viridian Therapeutics, Inc. shows a bullish technical trend, supported by positive indicators like the weekly MACD and Bollinger Bands, despite mixed performance signals and underperformance against the S&P 500 over the past 1Y and 3Y.

As of 26 August 2025, the technical trend for Viridian Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from Bollinger Bands and daily moving averages. The KST is also bullish on a weekly basis, while the Dow Theory indicates a mildly bullish stance. However, the OBV shows a mixed signal with a mildly bullish weekly reading but a mildly bearish monthly reading. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the 1Y and 3Y periods, with returns of -6.84% and -10.82% respectively, compared to the S&P 500's 17.14% and 70.41%. Over the 5Y period, the stock has outperformed with a return of 54.37% versus the S&P 500's 96.61%. Overall, the current technical stance is bullish, indicating a strengthening trend.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Jun 25

  • NET PROFIT(HY) Higher at USD -187.65 MM
  • RAW MATERIAL COST(Y) Fallen by -51.31% (YoY)
  • CASH AND EQV(HY) Highest at USD 1,199.99 MM
2

Risky - Negative EBITDA

3

Reducing Promoter Confidence

4

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,618 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-63.86%

stock-summary
Price to Book

3.14

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-101 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
66.72%
0%
66.72%
6 Months
124.64%
0%
124.64%
1 Year
61.57%
0%
61.57%
2 Years
88.5%
0%
88.5%
3 Years
18.04%
0%
18.04%
4 Years
72.29%
0%
72.29%
5 Years
95.54%
0%
95.54%

Viridian Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Viridian Therapeutics, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for Viridian Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from Bollinger Bands and daily moving averages. The KST is also bullish on a weekly basis, while the Dow Theory indicates a mildly bullish stance. However, the OBV shows a mixed signal with a mildly bullish weekly reading but a mildly bearish monthly reading. In terms of performance, the stock has underperformed the S&P 500 over the 1Y and 3Y periods, with returns of -6.84% and -10.82% respectively, compared to the S&P 500's 17.14% and 70.41%. Over the 5Y period, the stock has outperformed with a return of 54.37% versus the S&P 500's 96.61%. Overall, the current technical stance is bullish, indicating a strengthening trend....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-34.49%
EBIT Growth (5y)
-253.23%
EBIT to Interest (avg)
-106.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.98
EV to EBIT
-1.73
EV to EBITDA
-1.73
EV to Capital Employed
-53.24
EV to Sales
582.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-48.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 50 Schemes (35.46%)

Foreign Institutions

Held by 87 Foreign Institutions (15.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -54.92% vs -17.97% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-106.50",
          "val2": "-71.60",
          "chgp": "-48.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-100.70",
          "val2": "-65.00",
          "chgp": "-54.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,423,560.00%",
          "val2": "-1,002,597.20%",
          "chgp": "-42,096.28%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -83.33% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.24% vs -82.99% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-297.80",
          "val2": "-253.10",
          "chgp": "-17.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "1.80",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-208.60",
          "val2": "-237.70",
          "chgp": "12.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-990,182.10%",
          "val2": "-810,350.30%",
          "chgp": "-17,983.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-106.50
-71.60
-48.74%
Interest
0.50
0.60
-16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-100.70
-65.00
-54.92%
Operating Profit Margin (Excl OI)
-1,423,560.00%
-1,002,597.20%
-42,096.28%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -54.92% vs -17.97% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-297.80
-253.10
-17.66%
Interest
3.00
1.80
66.67%
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-208.60
-237.70
12.24%
Operating Profit Margin (Excl OI)
-990,182.10%
-810,350.30%
-17,983.18%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -83.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.24% vs -82.99% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Viridian Therapeutics, Inc. stock-summary
stock-summary
Viridian Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."